Apr 25, 2023
about HanchorBio Q&A
Apr 17, 2023
HANCHORBIO ANNOUNCES US IND CLEARANCE FOR THE MULTI-REGIONAL CLINICAL TRIAL OF HCB101 TO TREAT SOLID AND HEMATOLOGICAL MALIGNANCIES
HanchorBio Inc., a global clinical-stage biotechnology company developing innovative immuno-biomedicines, announced today that the US. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application to initiate a multi-regional clinical trial of its independently-developed novel drug candidate, HCB101, for the treatment of patients with advanced solid tumors or relapsed and refractory non-Hodgkin lymphoma.
Jul 24, 2023
HANCHORBIO ANNOUNCES TAIWAN FDA IND APPROVAL FOR THE MULTI-REGIONAL CLINICAL TRIAL OF HCB101 TO TREAT SOLID AND HEMATOLOGICAL MALIGNANCIES
HanchorBio Inc., a global clinical-stage biotechnology company developing innovative immuno-biomedicines, announced today that the Taiwan Food and Drug Administration (TFDA) has approved its investigational new drug (IND) application to initiate a multi-regional clinical trial of its independently-developed novel drug candidate, HCB101, for the treatment of patients with advanced solid tumors or relapsed and refractory non-Hodgkin lymphoma.